Stock Analysis
Krystal Biotech, Inc. Common StockKRYS
P/E 38.81×· 5Y range 26.47–455.30×· 30th percentile of history
Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
AnalystsStrong Buy19 analystsP/E 38.8× sits at the 30th percentile of its 5.059548254620124-year history.
Cash covers 8864% of debt · FY 2025.
PMP Verdict
Mixed fundamentals, fairly valued
Strengths
- Profitability95
- Financial Health75
Risks
- Growth0
Mixed picture — no clear quality or value edge.
Market context
-4.1% today· Z 1.9σ
Bull Case
- ✓Altman Z 51.3 — safe-zone balance sheet
- ✓ROE 19.8% — efficient capital deployment
What's happening with KRYS
Profile
Strong profitability and financial health; growth and valuation lag behind.
How is each axis scored?
- Valuation25/100 · Weak
- P/E vs own history (30th pct)20/25
- FCF yield (2.8%)5/25
- P/S (21.3x)0/25
- EV/EBIT (43.2x)0/25
- Growth0/100 · Weak
- Revenue CAGR (n/a)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (-4.8%)0/25
- Profitability95/100 · Strong
- ROIC (39.0%)25/25
- ROE (19.8%)20/25
- Net margin (54.8%)25/25
- Operating margin (44.9%)25/25
- Financial Health75/100 · Strong
- Altman Z (51.35)25/25
- Current ratio (9.95)25/25
- Interest coverage (-45.8x)0/25
- Net cash / debt (Net cash)25/25
- Quality52/100 · Moderate
- Piotroski F (6/9)15/25
- Beneish M (-2.19)12/25
- FCF conversion (107%)25/25
- Margin stability (σ 371.0%)0/25
- Moat50/100 · Moderate
- ROIC >12% years (2/7 yrs)0/25
- Median gross margin (93.9%)25/25
- FCF-positive years (2/8 yrs)0/25
- Worst-year net margin (worst 21.6%)25/25
Risk Flags
- ⚠SBC 12.4% of revenue — real dilution cost
- ⚠5 loss-making years in recent history
- ⚠Interest coverage -45.8× — thin debt cushion
About Krystal Biotech, Inc. Common Stock
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Show more
The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Headquarters: PITTSBURGH, PA · Employees: 295 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
25EP/E (TTM)38.8xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 26.5x–455.3x · 30th pct
P/FCF38.3xC
Grade C: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield2.8%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -11.7%–4.6% · 88th pct
P/S (TTM)21.27xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 3.7x–408.5x · 63rd pct
EV/EBIT43.2xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 24.6x–196.6x · 44th pct
EV/Sales21.4xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E40.8xD
Grade D: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio7.68xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio1.01B
Grade B: FairFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
95A+ROIC39.0%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE19.8%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA17.6%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin54.8%A
Grade A: HighNet Income / Revenue
Operating Margin44.9%A
Grade A: HighTTM EBIT / TTM Revenue
Gross Margin83.1%A
Grade A: PremiumGross Profit / Revenue
FCF Margin58.5%A
Grade A: HighFCF / Revenue
True FCF Margin46.1%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR—
Compound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth-4.8%D
Grade D: Decl.Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+36.2%D
Grade D: DilutiveShare count change over 5Y
SBC / Net Income22.6%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue12.4%D
Grade D: HighTTM stock-based comp / TTM Revenue
Financial Health
75B+Altman Z-Score51.35A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio9.95xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio7.73xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-45.8xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.01xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt88.64xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
52CPiotroski F-Score6/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.19C
Grade C: Gray zoneEarnings manipulation risk. < -2.22 Safe
FCF Conversion106.8%A
Grade A: StrongFCF / Net Income
Margin Stability371.0%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue3.3%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.32xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Mazzacco Catherine Filed | Mazzacco Catherine | Grant / award | +471 | |
Mazzacco Catherine Filed | Mazzacco Catherine | Grant / award | +1.2K | |
Sutherland Everett Rand Filed | Sutherland Everett Rand | Grant / award | +471 | |
Sutherland Everett Rand Filed | Sutherland Everett Rand | Grant / award | +1.2K | |
Mason Christopher Filed | Mason Christopher | Grant / award | +471 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Mason Christopher Filed | Mason Christopher | Grant / award | +1.2K | |
Gangolli Julian S Filed | Gangolli Julian S | Grant / award | +471 | |
Gangolli Julian S Filed | Gangolli Julian S | Grant / award | +1.2K |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
50CROIC >12% Years2/7 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)93.9%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years2/8 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor21.6%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$8.16
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$28.57
Cash & short-term investments per share (Finnhub)
Book Value / Share$45.92
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$9.34M
Total debt obligations (short + long term)
Cash & Equiv.$827.79M
Cash and short-term investments
Net Debt$-818.45MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$1.22B
Shareholders' equity (book value)
Asset / Liability11.68xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$9.37B
Current Market Capitalization
Beta0.65B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Krystal Biotech, Inc. Common Stock (KRYS)
KRYS is down 4.07% at the last close. Piotroski F-Score of 6/9 indicates mixed fundamentals for Krystal Biotech, Inc. Common Stock. Altman Z-Score of 51.35 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Krystal Biotech, Inc. Common Stock converts about 59% of revenue into free cash flow — strong cash generation.
- Company is effectively debt-free after netting cash.
- Interest coverage of -45.8× leaves little room for earnings shocks.
- Krystal Biotech, Inc. Common Stock posted a net loss in 5 of 8 available completed fiscal years (2017–2025).
- At a valuation score of 25/100, KRYS trades at a premium to its historical multiples (P/E 38.8).
See how KRYS ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all KRYS moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 14 | After-hours | 335.00 | +4.31% | 2.14 |
| Oct 5 | Regular | 338.71 | +5.10% | 3.31 |
| Oct 5 | After-hours | 331.94 | +3.00% | 2.10 |
| Sep 22 | Regular | 352.84 | +5.69% | 3.30 |
| Sep 22 | After-hours | 353.02 | +5.74% | 3.33 |
Frequently Asked Questions about KRYS
What is the current Krystal Biotech, Inc. Common Stock (KRYS) stock price?
KRYS is trading at $316.58 at the last market close, down 4.07% on the session. PreMarketPrice tracks KRYS pre-market, intraday and after-hours prices.
Is KRYS stock a buy right now?
PreMarketPrice's quantitative model rates Krystal Biotech, Inc. Common Stock's financial health at 75/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is KRYS stock overvalued?
Krystal Biotech, Inc. Common Stock trades at a trailing P/E of 38.8 and our valuation score rates it 25/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Krystal Biotech, Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for KRYS. The Earnings section lists recent reports and updates as dates are announced.
What sector does Krystal Biotech, Inc. Common Stock operate in?
Krystal Biotech, Inc. Common Stock operates in the Healthcare sector, within the Biological Products, (No Diagnostic Substances) industry. The Related Stocks section lists sector peers for comparison.
What does Krystal Biotech, Inc. Common Stock do?
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs.
About Krystal Biotech, Inc. Common Stock (KRYS) Stock
Krystal Biotech, Inc. Common Stock (KRYS) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry. As of the latest update, Krystal Biotech, Inc. Common Stock is trading at $316.58, down 4.07% on the day with a market capitalization of $9.4 billion. The financial health score for KRYS is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for KRYS stock.
KRYS Stock Analysis & Key Metrics
On PreMarketPrice, you can track Krystal Biotech, Inc. Common Stock (KRYS) across multiple dimensions:
- Pre-market price & movement: Real-time KRYS stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for KRYS with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Krystal Biotech, Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for KRYS.
- Sector peers: Compare KRYS against 5 other healthcare stocks on key financial metrics.
Is KRYS a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Krystal Biotech, Inc. Common Stock (KRYS) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Krystal Biotech, Inc. Common Stock (KRYS) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.